| CAS: | 176199-48-7 | ||
| 分子式: | C8H11NO4 | ||
| 分子量: | 185.18 | ||
| 英文名称: |
| ||
| 用途: | Eglumegad is a highly potent, efficacious and selective group II (mGlu2/3) receptor agonist, used for treatment of anxiety and stress-related disorders. |
| 货号 | 品牌 | 产品名称 | 规格 | 包装、参考价格 | |||
| E911116 | MACKLIN | Eglumegad | ≥98% | 400元/1mg; 1020元/5mg; 1530元/10mg; 4981元/50mg; | 咨询 | ||
储存:-20°C,密闭,干燥 | |||||||
| HY-18941 | MCE | Eglumegad,176199-48-7_MCE(MedChemExpress) | 1650元/10 mM * 1 mL in Water; 1500元/5 mg; 2500元/10 mg; 5000元/25 mg; | 咨询 | |||
MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。 EglumegadMCE 国际站:Eglumegad 品牌:MedChemExpress (MCE) 货号:HY-18941 CAS 号:176199-48-7 生物活性: Eglumegad (LY354740) 是一种高效且选择性强的 II 组 (mGlu2/3) 受体激动剂,对转染的人类 mGlu2 和 mGlu3 受体的 IC50 分别为 5 nM 和 24 nM。 体外研究(In Vitro):Eglumegad (LY354740) 下调点 1014、1822 (缺氧上调蛋白 1)、4513 (蛋白质二硫化物异构酶 3 的同种型)、6204、6312、7306 (26S 蛋白酶体非 ATP 酶调节亚基 7) 和蛋白点 1013和 6005 (destrin),并上调小鼠皮层神经元中的斑点 6507 (塌陷蛋白反应介质蛋白 1)[2]。 MCE尚未独立确认这些方法的准确性。 仅供参考。 体内研究(In Vivo):Eglumegad (LY354740) 下调点 1014、1822 (缺氧上调蛋白 1)、4513 (蛋白质二硫化物异构酶 3 的同种型)、6204、6312、7306 (26S 蛋白酶体非 ATP 酶调节亚基 7) 和蛋白点 1013和 6005 (destrin),并上调小鼠皮层神经元中的斑点 6507 (塌陷蛋白反应介质蛋白 1)[2]。 MCE尚未独立确认这些方法的准确性。 仅供参考。 分子量:185.18 Formula:C8H11NO4 性状:固体 颜色:White to off-white 运输条件:美国大陆地区的室温;其他地区可能有所不同。 储存方式:粉末 -20°C 3年 Animal Administration [1][4]:Mice[1]In Experiment 1A wild-type (female: N=6; male: N=5) and Gria1−/− mice (female: N=7; male: N=8) first receive 30 trials of drug-free testing (five trials per day for 6 days). Each animal is then tested on rewarded alternation following an injection of either Eglumegad (LY354740) (15 mg/kg) or vehicle. After injection animals are returned to the home cage for 30 min before behavioural testing commenced. Each animal is given 10 trials of rewarded alternation in the T-maze. Mice are given a maximum of 120 s to a complete a trial. At least 24 h after the first round of drug testing the animals are re-tested in the absence of any drug treatment to ensure that there are no long-term effects of the drug, and that the mice maintain a high level of alternation performance. Twenty-four hours after this re-testing, mice receive a further 10 trials of rewarded alternation testing, but now under the drug condition that they have not previously received. The order of drug exposure is counterbalanced within genotype and sex as far as possible given the numbers of mice. In all stages, the number of trials in which the animal alternated, as well as time taken to run from the start arm to the food well on the sample run (sample latency), and the time taken to run from the start arm to making a choice on the choice run (choice latency), are recorded. Latencies are measured by the experimenter using a stopwatch. The experimenter is blind to the genotype and drug allocations of the animals throughout testing. In Experiment 1B, separate groups of male wild-type (N=7) and Gria1−/− mice (N=7) undgo the same procedure as Experiment 1A but now they receive either vehicle or a higher dose of Eglumegad (LY354740) (30 mg/kg). Subsequently, in Experiment 1C, to investigate the potential effects of increased proactive interference, the procedure used in Experiment 1B is repeated in the same mice, using the same drug dose (30 mg/kg), but now using a modified testing protocol in which the interval between trials is reduced to 20 s. Rats[4]Two experiments are conducted. The first experiment compares the effects of LY354740 (10 mg/kg, i.p., neutralized to a pH ~ 7.4) or vehicle (0.9% saline neutralized to pH ~ 7.4) in rats remaining in their home cages or rats exposed to 2 h of immobilization stress in plastic cones (n=7, cage control/vehicle; n=7, cage control/LY354740; n=6, stress/vehicle; n=6, stress/Eglumegad (LY354740)). The second experiment compares two lower LY354740 doses (1 and 3 mg/kg, i.p.) or vehicle in rats exposed to a 2-h period of immobilization stress to rats treated with vehicle in their home cages (n=4 for all groups). All animals are injected with either Eglumegad (LY354740) or vehicle 15 min prior to being placed in plastic cones with the open end securely closed. All immobilized rats are placed in plexiglass chamber with animal bedding on the bottom; brought to a quiet room outside of the animal colony; and immediately placed in a plastic cone. Two hours after being placed in the plastic containers, the rats are decapitated. The brains are removed and frozen on dry ice, and stored at −80°C. MCE尚未独立确认这些方法的准确性。 仅供参考。 文献引用:MCE 顾客使用本产品发表 4 篇科研文献 提供质量检测报告:Data Sheet、SDS、COA、HNMR、RP-HPLC、MS、产品使用指南 产品活性:Eglumegad (LY354740) 是一种有效,选择性的 group II (mGlu2/3) receptor 激动剂,对人 mGlu2 和 mGlu3 受体的 IC50 分别为 5 nM 和 24 nM。 相关产品:LY341495 | MTEP hydrochloride | LY379268 | L-AP4 | LY2794193 | VU0650786 | MTEP hydrochloride (Standard) | D-AP5 | VU6010572 | LY379268 (Standard) | Xanomeline | LY2812223 热门产品线:抑制剂 | 稳定性同位素标记物 | 脂质 | 糖类 Trending products:Inhibitors | Isotope-Labeled Compounds | Lipids | Saccharides MCE 抑制剂: MedChemExpress 信号通路产品覆盖细胞凋亡、自噬、细胞周期与 DNA 损伤、表观遗传、GPCR/G 蛋白、免疫与炎症、JAK/STAT、MAPK/ERK、膜转运体与离子通道、代谢酶与蛋白酶、神经信号、NF-κB、PI3K/Akt/mTOR、PROTAC、蛋白酪氨酸激酶/受体酪氨酸激酶、干细胞/Wnt、TGF-β/Smad 及维生素 D/核受体等研究方向,为肿瘤、感染、炎症与免疫、神经系统疾病、代谢性疾病、心血管疾病和内分泌研究提供多维度的产品选择,助力客户发表文献超 80,000 篇。 相关产品可根据具体情况提供化学结构、作用靶点、生物活性、纯度、溶解度、体内外研究信息、参考文献及质量分析报告 (COA)等资料。 客户发表文献: 参考文献: 品牌介绍:
| |||||||